pyrazinamide
Selected indexed studies
- Pyrazinamide. (Tuberculosis (Edinb), 2008) [PMID:18486055]
- Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial. (Am J Respir Crit Care Med, 2024) [PMID:39012226]
- Pyrazinamide resistance in rifampicin discordant tuberculosis. (PLoS One, 2022) [PMID:36129921]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pyrazinamide. (2008) pubmed
- Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial. (2024) pubmed
- Pyrazinamide resistance in rifampicin discordant tuberculosis. (2022) pubmed
- Anti-Tubercular Activity of Pyrazinamide Conjugates: Synthesis and Structure-Activity Relationship Studies. (2023) pubmed
- Pyrazinamide may possess cardioprotective properties. (2019) pubmed
- Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis. (2016) pubmed
- Our Love-Hate Relationship With Pyrazinamide. (2021) pubmed
- Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide. (2019) pubmed
- Pyrazinamide. (1993) pubmed
- Impact of the host environment on the antitubercular action of pyrazinamide. (2019) pubmed